Hospital.Help

Indianapolis – In addition to Novo Nordisk, which recently received approval for insulin Icodec in Europe, its competitor Lilly also wants to introduce an ultra-long-acting insulin that allows once-weekly dosing. The conditions for approval of insulin Efsitora Alpha for type 2 diabetes were created by the phase 3 study, the results of which were presented at this year’s annual meeting of the European Association for the Study of…